Wang et al.28 recently demonstrated that although myostatin pathway inhibition (Activin receptor type IIb antagonist) was capable of restoring muscle size in STZ-treated mice, it did not improve hyperglycemia. The gene discussed is ACVR2B; the disease is Hyperglycemia.